Equity Raise Post-Transaction Report
Animalcare Group plc
("Animalcare", the "Company" or the "Group")
Equity Raise Post-Transaction Report
5 December 2024. In accordance with the Statement of Principles (November 2022) published by the Pre-Emption Group, Animalcare Group Plc (AIM: ANCR), the international animal health business, announces the following post transaction report in connection with the Company's non-pre-emptive issue of equity securities, as announced on 3 December 2024.
Terms defined in the fundraise announcement issued on 3 December 2024 (the 'Fundraise Announcement') have the same meanings in this announcement unless the context provides otherwise.
|
Name of Issuer |
Animalcare Group plc |
|
Transaction Details |
The Company issued 8,602,150 new ordinary shares in total pursuant to the Fundraise, representing approximately 14.2% of the Company's existing issued ordinary shares prior to the Fundraise.
Settlement and admission of the Placing Shares took place at 8.00 am on 5 December 2024. |
|
Use of Proceeds |
As set out in the Fundraise Announcement the proceeds of the Fundraise (net of transaction costs) will be used to part fund the cash consideration payable by the Company for the conditional acquisition of the entire issued share capital of Randlab Pty Ltd, Randlab Australia Pty Ltd (and its wholly-owned subsidiary, Randlab (New Zealand) Limited) and Randlab Middle East Veterinary Medicine Trading Single Owner L.L.C. , a privately-owned Australian-based equine veterinary business (the "Acquisition"). The Fundraise will also enable the Company to maintain an appropriate leverage position that enables Animalcare to continue to invest in its growth strategy, including future inorganic investment opportunities. |
|
Quantum of Proceeds |
The aggregate gross proceeds from the Fundraise amounted to approximately £20 million. |
|
Discount |
The Issue Price of 232.5 pence per Placing Share represented a 5.1% discount to the closing price on 2 December 2024. |
|
Allocations |
Soft pre-emption has been adhered to in the allocations process, where possible. The Company was involved in the allocations process, which has been carried out in compliance with the MIFID II Allocation requirements. |
|
Consultation |
Stifel and the Company undertook a pre-launch wall-crossing process, including consultation with certain major shareholders, to the extent reasonably practicable and permitted by law. |
|
Retail |
Following discussions between Stifel and the Company, it was decided that a retail offer would not be included in the Placing. The Placing structure was chosen to minimise time to completion and complexity. |
|
For further enquiries, please contact: |
|
|
|
|
|
Animalcare Group Plc |
+44 (0)1904 487 687 |
|
Jenny Winter, Chief Executive Officer |
|
|
Chris Brewster, Chief Financial Officer Media/investor relations |
|
|
Stifel Nicolaus Europe Limited (Sole and Exclusive M&A Adviser, Sole Bookrunner and Nominated Adviser) |
+44 (0) 20 7710 7600 |
|
Ben Maddison Charles Hoare Nicholas Harland Francis North
|
|
Forward Looking Statements
Statements that are not historical facts, including statements about Animalcare or its management's beliefs and expectations, are forward-looking statements. Forward-looking statements, by their nature, involve substantial risks and uncertainties as they relate to events and depend on circumstances which will occur in the future and actual results and developments may differ materially from those expressly stated or otherwise implied by these statements.
These forward-looking statements are statements regarding Animalcare's intentions, beliefs or current expectations concerning, among other things, its results of operations, financial condition, prospects, growth, strategies and the industry and markets within which it operates.
These forward-looking statements relate to the date of this announcement and Animalcare does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after such date.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 days ago City of London Investment Group
- 2 days ago Aberdeen Group plc
- 2 days ago NATWEST GROUP
- 2 days ago Ondo Insurtech
- 2 days ago Banco Santander S.A.